TABLE 1.
Potency of anti-CCR5 MAbs in inhibiting HIV-1 envelope-mediated membrane fusion, viral entry, gp120-CCR5 binding, and chemokine signalinga
| MAb | Epitope(s) | IC50 (μg/ml) for inhibition of:
|
|||
|---|---|---|---|---|---|
| Membrane fusion | Viral entry | gp120 binding | Calcium flux | ||
| PA8 | Nt | ||||
| PA9 | Nt-ECL2 | 0.24 | |||
| PA10 | Nt-ECL2 | 0.13 | |||
| PA11 | Nt | 25.5 | 0.33 | ||
| PA12 | Nt | 10.0 | 0.24 | ||
| PA14 | Nt-ECL2 | 1.7 | 0.024 | 1.58 | 45 |
| 2D7 | ECL2 | 1.6 | 0.026 | 1.38 | 6.4 |
a
For comparative purposes, we have summarized the IC50 obtained for the anti-CCR5 MAbs in the various assays. IC50 are reported only for MAbs that could inhibit >90% of fusion, entry, or binding.